COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Journal of Antimicrobial Chemotherapy

Volumn 75, Issue 7, 2020, Pages 1667-1670

  Zhou, Dan ^a   Dai, Sheng Ming ^b   Tong, Qiang ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ADVERSE DRUG REACTION; ARTICLE; CORONAVIRUS DISEASE 2019; CYTOKINE STORM; DISEASE EXACERBATION; DRUG SAFETY; EPIDEMIC; HUMAN; T LYMPHOCYTE ACTIVATION; ADVERSE EVENT; ANTIVIRAL ACTIVITY; CHINA; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG INHIBITION; INFECTION PREVENTION; PUBLICATION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; ADULT RESPIRATORY DISTRESS SYNDROME; BETACORONAVIRUS; CORONAVIRUS INFECTION; CYTOKINE RELEASE SYNDROME; LYMPHOCYTE ACTIVATION; PANDEMIC; T LYMPHOCYTE; VIROLOGY; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; CYTOKINE RELEASE SYNDROME; DISEASE PROGRESSION; HUMANS; HYDROXYCHLOROQUINE; LYMPHOCYTE ACTIVATION; PANDEMICS; PNEUMONIA, VIRAL; RESPIRATORY DISTRESS SYNDROME, ADULT; T-LYMPHOCYTES;

EID: 85083106854     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkaa114     Document Type: Article

References (24)

1. Xu X, Chen P, Wang J et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63: 457-60
2. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; doi:10.1001/jama.2020.1585
3. Shimabukuro-Vornhagen A, Godel P, Subklewe M et al. Cytokine release syndrome. J Immunother Cancer 2018; 6: 56
4. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71
5. Sheahan TP, Sims AC, Graham RL et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653
6. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8
7. Lotteau V, Teyton L, Peleraux A et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990; 348: 600-5
8. Wu SF, Chang CB, Hsu JM et al. Hydroxychloroquine inhibits CD154 expression in CD4(!) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther 2017; 19: 183
9. van den Borne BE, Dijkmans BA, de Rooij HH et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 55-60
10. Kuznik A, Bencina M, Svajger U et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-804
11. Ewald SE, Lee BL, Lau L et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008; 456: 658-62
12. Hacker H, Mischak H, Miethke T et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17: 6230-40
13. Vollmer J, Tluk S, Schmitz C et al. Immune stimulationmediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J ExpMed2005; 202: 1575-85
14. An J, Woodward JJ, Sasaki T et al. Cutting edge: antimalarial drugs inhibit IFN-b production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol 2015; 194: 4089-93
15. VincentMJ, Bergeron E, Benjannet S et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69
16. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res 2015; 202: 120-34
17. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16: 155-66
18. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 2017; 5: e00293
19. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I et al. Predictors ofmajor infections in systemic lupus erythematosus. Arthritis Res Ther 2009; 11: R109
20. Srinivasa A, Tosounidou S, Gordon C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue JRheumatol 2017; 44: 398
21. Jorge A, Ung C, Young LH et al. Hydroxychloroquine retinopathy-implications of research advances for rheumatology care. Nat Rev Rheumatol 2018; 14: 693-703
22. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ Ro-antibody-associated cardiacmanifestations of neonatal lupus. Circulation 2012; 126: 76-82
23. Lisney AR, Szelinski F, Reiter K et al. Highmaternal expression of SIGLEC1 on monocytes as a surrogatemarker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Ann Rheum Dis 2017; 76: 1476-80
24. Furst DE, Lindsley H, Baethge B et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum1999; 42: 357